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Abstract 
Drug development is a very costly and lengthy process, while repositioned or repurposed drugs 
could be brought into clinical practice within a shorter time-frame and at a much reduced cost. 
The past decade has observed a massive growth in the amount of data from genome-wide 
association studies (GWAS). The rich information contained in GWAS data has great potential 
to guide drug discovery or repositioning. Here we provide an overview of different 
computational approaches which employ GWAS data to guide drug repositioning. These 
methods include selection of top candidate genes from GWAS as drug targets, deducing drug 
candidates based on drug-drug and disease-disease similarity, searching for reversed expression 
profiles between drugs and diseases, pathway-based methods as well as repositioning based on 
analysis of biological networks. Each method is illustrated with examples, and their respective 
strengths and limitations are discussed. Finally we discussed several areas for future research.  
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Introduction 
Drug development is a very costly and lengthy process, which typically involves multiple 
processes from drug target discovery, clinical trials to final approval by the FDA or other 
government agencies. The estimated cost of developing a new drug is around USD2.6 billion[1]. 
As a result, there have been increased interests to repurpose or reposition existing drugs for new 
usage. Repositioned drugs can be brought to clinical practice in a much shorter time-frame and at 
a much lower cost, as these drugs have gone through pharmacokinetic/pharmacodynamic and 
safety profiling during development. Besides existing drugs with known indications, drugs that 
are shelved due to failure in clinical trials may also serve as candidates for repositioning. In fact, 
repurposing these drugs may serve to recover the high cost that went into developing them.  
 
  In practice, many drugs in wide use today stem from repositioning. Two classical examples are 
Sildenafil and thalidomide[2], which are now commonly used to treat erectile dysfunction and 
multiple myeloma, although they were not originally designed for these indications. However, 
these and many other drugs are discovered based on serendipity alone while computational 
repositioning approaches offers a more systematic way (as well as lower cost when compared to 
experimental methods) of discovering such unexpected relationships between drugs and diseases. 
 
   The past decade has witnessed a massive rise in the amount of ‘omics’ and other forms of 
biomedical data (e.g. electronic health records), which makes computational approaches an 
attractive option to prioritize repositioning candidates. One of the fastest growing types of data 
comes from genome-wide association studies (GWAS), a high-throughput technique that 
interrogates the whole genome for common genetic variations that contribute to diseases or traits. 
GWAS have been highly successful in unraveling the genetic basis of many complex traits or 
diseases[3], and many statistical/computational methodologies have been developed to improve 
the power in detecting susceptibility variants. However, from a clinical point of view, one of the 
most important questions would be: could GWAS findings be translated into opportunities for 
drug discoveries or repositioning? This question also calls for more innovative approaches to 
analyzing GWAS data with a translational focus. In this article, we shall review several 
categories of methods for prioritizing drug repositioning candidates, highlighting their 
applications as well as their respective strengths and limitations.  
 
Overview of GWAS and its potential in guiding drug discoveries/ 
repositioning 
Genome wide association studies (GWAS) aims to decipher associations between common 
genetic variants and traits or diseases. Typically the genetic variant studied is a single nucleotide 
polymorphism (SNP), and current GWAS arrays allow millions of SNPs across the whole 
genome to be interrogated at the same time. Variants that are not genotyped can also be imputed 
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with appropriate reference panels[4]. The most common design for GWAS is a population-based 
case-control study, in which we recruit subjects with and without the disease, and search for 
SNPs with significant differences in allele frequencies between the two groups. However, 
GWAS can also be used to study continuous or time-to-event outcomes. A full GWAS workflow 
tutorial can be found in [5]. 
 
   A number of GWAS resources are available online, and one of the largest is the GWAS catalog 
(https://www.ebi.ac.uk/gwas/). It is a structured repository of the summary statistics for a large 
variety of traits. As of Oct 14, 2019, the GWAS Catalog contains 7796 publications and 159202 
associations, showing the popularity of GWAS and the vast amount of data available for mining. 
Other useful resources include the LD-hub (http://ldsc.broadinstitute.org/ldhub/), GWAS 
summary statistics from the UK Biobank (http://www.nealelab.is/uk-biobank) and dbGaP 
(https://www.ncbi.nlm.nih.gov/gap/) which allows access to raw genomic data to authorized 
users.  
 
   In order to treat a disease, it is critical to understand the causal factors, which is one of the 
main goals of GWAS - to understand the underlying biological mechanisms. Unlike Mendelian 
diseases where typically only one or few genes cause the condition, complex disease arises as a 
combination of a multitude of genetic and environmental causes [6]. GWAS has the niche of 
identifying risk loci for a disease without a priori hypotheses [7]; hence it is useful in identifying 
novel genetic loci that are beyond our current understanding of the disease. At the same time, the 
development of drugs with new mechanisms of action has become increasingly difficult; GWAS 
data therefore hold great potential in guiding drug discovery. Another important advantage is that 
for many diseases (e.g. psychiatric disorders[8] and cancers[9] ), current cell-based or animal 
models are unable to fully mimic the human condition, limiting the success rate of translating 
preclinical findings into clinical practice. On the other hand, GWAS are based on clinical 
samples of patients with actual phenotype data, and may more realistically reflect the genetic 
basis of the condition under study.  
 
  In an important study, Nelson et al.[10] showed that the proportion of drugs with direct genetic 
support increases along the development pipeline, rising from 2.0% at the preclinical stage to 
8.2% among the approved drugs. In a more updated analysis by King et al.[11], they reported 
similar findings that genetically supported targets were more likely to be successful in Phases II 
and III, especially when the genes implicated are likely to be causal.  
 
  However, GWAS has been criticized for the interpretability of its findings and small effect 
sizes of most susceptibility variants. Approximately 90% of the SNPs found by GWAS are 
located in non-coding regions, suggesting that these variants may be associated with diseases 
through other means such as splicing, small ncRNA, lnRNA, promoter or transcription factor 
(TF) [6,12,13]. It is also possible that some SNPs are in linkage disequilibrium (LD) with the 
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causal variants but are not causal themselves. However,  an increasing number of methods and 
tools are available to uncover the functional role of SNPs and prioritize the causal genes 
involved, which will be discussed in detail in the sections below. Another concern is that most 
susceptibility variants found so far only confer small effects to diseases or traits. However, small 
effect sizes of individual SNPs do not necessarily dictate low efficacy when we target the 
corresponding protein by a drug. For instance, one of the most successful lipid lowering drugs is 
statins which targets HMG Co-A reductase (HMGCR).  This target is also suggested by genetic 
evidence, since GWAS of LDL-cholesterol (LDL-C) also implicated SNPs in this loci. However, 
the effect size of SNP(s) at HMGCR is relatively modest [14,15] (e.g. G allele of rs17238484 
allele was associated with ~0.06 mmol/L reduction in LDL-C), but the effect size of statins is 
much larger[16]. Therefore, modest effect sizes of genetic variations do not exclude therapeutic 
potential of the corresponding targets.  
Approaches to computational drug repositioning 
Selecting top candidate genes from GWAS as targets for drug 
repositioning 
Perhaps the most intuitive approach to drug repositioning with GWAS is to focus on the top 
candidate genes identified from the study. We may first map the SNP onto corresponding genes, 
preferably with knowledge of the functional role of the SNP (e.g. whether it affects expression or 
regulation of a gene). In the next step, we may query these target genes in drug databases where 
information about drug-gene and drug-disease indication can be retrieved. Finally, drug 
repositioning opportunities present itself as a ‘mismatch’ between the drug indication and the 
disease of interest. For example, we may find a drug that targets the GWAS top gene but it has 
not been used for treating the disease of interest yet. The target genes retrieved from GWAS 
serve as a connection between the disease and drugs.  
 
   Mapping susceptibility SNPs from GWAS to the corresponding functionally important gene is 
a fundamental step for this approach of repositioning, and is a topic of active research [6,17–19]. 
However, this can be a challenging process since many SNPs are located in non-coding regions 
where the functional roles of variants are not fully understood. There are several comprehensive 
reviews on computational approaches and tools for finding relevant genes from GWAS hits 
[6,17–20]. We shall highlight a few approaches below and discuss the limitations of this drug 
repositioning methodology. 
An overview of SNP to gene mapping 
Following Edwards et al [17], mapping GWAS variants to the ‘target’ (i.e. functionally relevant) 
genes can be broken down into several steps. The first step involves fine mapping of the SNPs 
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associated with the trait of interest. Briefly, fine mapping is a process of identifying the most 
probable causal candidate SNP within the  identified genetic loci[6,21,22] (since the GWAS 
chips are not designed to necessarily sequence the functional SNP, rather SNPs that are the most 
representative [ie ‘tag’ SNPs] are chosen [17]). The second step involves in silico methods for 
annotation and characterization of the functional impact of identified SNPs. Functional 
significance of the fine-mapped loci can be investigated with information such as chromatin 
accessibility, TF binding, DNA protein interactions, histone modification, DNA methylation and 
chromatin interactions etc. Another common approach is to look for overlap of the identified 
variants with expression- or other types of quantitative trait loci (QTL). Finally, if resources 
allow, one may perform further experiments in cell lines or animal models to ascertain the role of 
the target genes.  
Using functional annotation to map associated SNPs to genes 
Given that most associated SNPs are located in non-coding regions, it is logical to hypothesize 
that these SNPs may regulate gene expressions in certain ways to affect disease risks. The 
Encyclopedia of DNA elements (ENCODE) is one of the earliest initiatives to systematically 
characterize functional elements in the human genome. ENCODE aims to extensively 
characterize multiple genetic elements, examples of which include TF binding regions, 
chromatin and DNA accessibility, histone modification, epigenetics and 3D chromatin 
interactions. The project employs a variety of techniques including RNA-seq, DNase-seq, 
FAIRE-seq and ChIP-seq etc., which provide very rich data for functional annotation. Other 
useful resources for functional annotation include modENCODE, the NIH Roadmap 
Epigenomics Project, GWAS3D [23] and its successor GWAS4D [24]. One point to note is that 
the genes closest to the associated SNP may not necessarily be the most functionally relevant 
gene; a recent study suggested that the likely causative genes are often >2Mbp from the index 
SNP [25]. To improve the reliability of gene mapping, it is advisable to employ a variety of 
annotation methods to prioritize the best genes as drug target candidates.  
 
Using expression-QTL (eQTL) to map associated SNPs to genes 
Besides prioritizing the corresponding ‘target’ gene for the associated SNPs, it is preferable to 
also determine the directionality of such relationships to facilitate drug repositioning. One 
important question is whether the SNP causes changes in gene expression, and if so, what is the 
direction of change and which tissues are involved. For example, if the identified SNP causes an 
upregulation of gene X leading to increased risk of a disease, then an inhibitor of its protein 
product may be considered a repositioning candidate. One of the largest eQTL resources is the 
Genotype-Tissue Expression (GTEx) project (https://gtexportal.org/home/), which includes 
eQTL data from 49 tissues of over 800 subjects. However, most of the subjects are Europeans 
with male predominance (~67%), and the sample size may still be insufficient to detect eQTL 
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with modest effects. Another related approach is to use tools such as PrediXcan[26] to impute the 
expression changes based on raw genotype or GWAS summary data.  
Querying drug databases for repositioning candidates 
After identifying the most relevant genes from associated SNPs, finding candidate drugs which 
target the selected genes is relatively straightforward. For instance, in a recent attempt to 
repurpose drugs for inflammatory bowel disease (IBD), Grenier et al [27] first selected the most 
likely causal SNPs by Bayes factor within each locus, then these SNPs were mapped to relevant 
genes by functional annotation. Finally, drugs that may be repositioned for treating IBD (if not 
already known) were derived from these genes using a web-based tool Gene2Drug [28] (see the 
section: Using pathway analysis in combination with other approaches). Other reports pulled 
drug data from multiple databases including TTD, Pandrugs, PharmGKB and DrugBank to 
derive drug-target relationships [29–35].  
Limitations 
There are several limitations of using the top candidates genes for direct drug repositioning. 
Firstly, the top genes identified from GWAS may not be easily druggable. Finan et al. performed 
a comprehensive analysis on the druggability of genes [36]. They estimated that only 4,479 (22%) 
of the 20,300 protein coding genes are druggable (or already targeted by a drug). Second, 
focusing on the effect of the top SNPs may miss biologically meaningful target genes with small 
effect sizes [37–39]. Third, focusing on single candidate gene may miss multi-target drugs, 
which could be more effective than single-target ones for some conditions [40]. Also, recently 
increasing attention has been placed on development of multi-target drugs [41,42]. Fourth, as 
discussed earlier, due to the complexity of the human genome, there is no perfect way to proper 
annotation. As a result, different studies may have employed different  (sometimes incomplete) 
annotation procedures, and integrating various annotation approaches is not straightforward.  
 
 
 
 
 
 
 
Table 1: Summary and comparison of drug repositioning approaches using GWAS data  
Approach Brief description Pros Cons Selected  
references 
Using functional 
annotation for 
identifying top 
Map GWAS SNPs to 
corresponding functionally 
related genes with 
Relatively clear biological 
interpretation; 
straightforward  
Usually only single or a 
few genes are examined; 
may potentially miss 
[6,17,19] 
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candidate genes 
(then link to 
drugs)  
functional annotation tools computation and low 
computational cost; 
multiple databases 
available for annotation 
multi-target drugs; 
directionality of effect 
may not be clear; 
functional annotation 
information for some 
SNPs may be missing; not 
all genes are directly 
druggable 
Using eQTL data 
for identifying 
top candidate 
genes (then link 
to drugs)  
Map GWAS SNPs to 
corresponding gene using 
eQTL information 
Directionality indicated; 
covers SNPs that affects 
multiple genes at the same 
time; easy to implement 
GTEx data still limited in 
sample size, and bias 
towards European 
population; not all SNPs 
may affect gene 
expression 
[43–45] 
Pathway/gene- 
set analysis 
Repositioning drug based 
on pathway or gene-set 
analysis of GWAS results 
Consideration of drug 
effect on a genome-wide 
scale; multi-target drugs 
included; inclusion of risk 
loci with small effect size  
individually but good 
therapeutic potential when 
combined as a pathway 
Definition of pathways 
can be complicated; 
incomplete 
characterization of 
pathways for all drugs; 
directionality of effect 
may not be clear 
[38,46] 
Similarity-based: 
Drug-drug or 
disease-disease 
similarity 
Evaluating similarity 
between drugs and diseases 
effect may reveal novel 
drug-disease relationships 
Intuitive in concept; simple 
computation; less detailed  
understanding of drug 
mechanism required 
‘Similarity’ may not be 
easy to define; difficulty 
in integrating different 
sources of similarity 
measures; relatively hard 
to uncover drugs with 
novel mechanisms of 
actions 
[47,48] 
Reversed 
expression 
pattern between 
drugs and 
diseases  
A drug with expression 
profile opposite to that of a 
disease are candidate 
therapeutic agents 
Considers data across 
many genes instead of the 
most significant ones; 
imputed expression readily 
available for many tissues 
and from large GWAS 
samples, and less 
susceptible to confounding 
and reverse causality; 
understanding of drug 
mechanism not required; 
relatively better at 
uncovering drugs of novel 
mechanism 
Expression reversal may 
not be the only drug 
mechanism; limitation of 
cell lines (cannot fully 
model human conditions); 
imputation accuracy of 
some genes may be poor  
[49,50] 
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Network-based 
methods 
Integration of multiple 
sources of data regarding 
drugs, proteins, genes and 
diseases relationships to 
reveal novel drug-disease 
connections 
Flexible; ability to 
integrate multiple sources 
of data; well established 
network analysis methods 
from other fields 
Integrating data with 
different nature and 
potentially different kinds 
of bias is difficult; 
complicated parameter 
optimization; difficulty in 
determining edge 
strength; relatively less 
capable of revealing 
unexpected repositioning 
candidates 
[51–55] 
 
Drug repositioning based on pathway or gene-set analysis  
Pathway or gene-set analysis (as opposed to single gene or SNP-based studies) offers a more 
macroscopic view of the biological processes underlying diseases and drug effects. The key idea 
behind pathway analysis is to organize various functionally or biologically relevant genes 
together and consider the overall effect. As mentioned earlier, approaches that consider only 
individual SNPs or genes may miss biologically meaningful associations of modest effect sizes 
[56]. Biological pathways group genes based on their function; on the other hand, ‘gene-sets’ can 
be any set of functionally related genes or a set based on arbitrary criteria set by the researcher 
(in this context, drug targets or ‘effector genes’). For the purpose of this review, we refer to both 
of these grouping methods as ‘pathways’. Several examples of applications are discussed below.  
 
   De Jong et al. [48] studied repositioning candidates for schizophrenia by a gene-set analysis 
based on GWAS summary statistics, where each drug pathway is defined by pharmacological 
profiles and chemical binding affinity. The analysis highlighted several candidates reaching a 
suggestive level of significance, including two dopamine receptor antagonists and a tyrosine 
kinase inhibitor. In another recent work, So et al. [57] investigated whether findings from GWAS 
may be used to guide drug repositioning for depression and anxiety disorders. Drug-effector 
gene-sets were extracted with DSigDB and gene-based significance from GWAS was computed 
by FASTBAT [58]. Then pathway analyses (following the principle of MAGMA[59]) were 
conducted to look for enrichment of GWAS results for specific drugs. Interestingly, the 
repositioning hits identified are largely enriched for known psychiatric drugs or those included in 
clinical trials. Enrichment was seen for antidepressants and anxiolytics but also for 
antipsychotics. The study also revealed other repositioning candidates with literature support. 
Note that the above two studies did not only focus on the top genes but also considered the actual 
significance level of each gene.  
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  Another approach was presented by Jhamb et al. [60]. The authors first obtained GWAS data 
from STOPGAP [61]. After SNPs with p<5e-8 are mapped to genes, these genes were mapped to 
their respective pathways with MetaBase, a manually curated software suite that contains 
interaction data. The main novelty is that the authors considered an expanded set of GWAS ‘hits’ 
by including genes in related pathways as well. Finally a 2 by 2 table is constructed for each 
disease to look for over-representation of the (expanded) GWAS hits among drug targets 
indicated for each disease.  
    
   Yet another work by Gaspar et al. investigated drug repositioning opportunities for 
schizophrenia using GWAS data [62]. They also proposed a new visualization approach and 
studied how increased sample size of the original GWAS may improve the yield of drug 
repositioning. Pathway analysis can also be combined with other methods. Mӓkinen et al. [37] 
first mapped cardiovascular disease (CVD) associated-SNPs to genes with eQTL, then 
investigated the enrichment of these ‘e-SNPs’ among known biological pathways. After 
obtaining the CVD pathway set, the pathways are augmented with co-expression analysis and 
subsequently placed in a Bayesian network model of gene-gene interactions. By integrating a 
larger variety of sources of omics data, the identified genes may serve as better targets for 
repositioning.  
 
  Another tool combining pathway analysis and perturbation library is Gene2Drug [28], which is 
used by Grenier et al. [27] (see discussion above). Gene2Drug takes a single gene as input, and 
aims to discover drugs linked to the input gene. The program extracts drug-related pathways 
based on perturbation data from CMap  (see section below), then generates the subset of 
pathways including the input gene.  
    
   Pathway-based analysis is a flexible approach and several extensions are possible. For example, 
in clinical practice comorbid diseases are very common, and it will be preferable to find drugs 
that target both diseases at the same time. A recent study proposed a pathway-based approach to 
address this problem. Wong et al.[63] first employed a false discovery rate (FDR)-based 
approach to uncover genetic loci shared between depression/anxiety and cardiometabolic 
diseases from GWAS summary data. The shared loci were then subject to pathway analysis to 
uncover repositioning candidates, many of which are supported by the literature. Also, while the 
focus of this review is on repositioning using GWAS data, the pathway-based approach can be 
readily extended to handle other types of  human genomic data. For example, a recent study 
showed by pathway analysis that de novo mutations may be used to guide drug discoveries for 
neuro-psychiatric disorders[64]. Readers may also refer to [65] for further discussions on the 
potential of GWAS data in drug discovery for neuro-psychiatric disorders. 
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Limitations 
First, defining a pathway is complicated because feedback inhibition and compensatory 
mechanism is almost ubiquitous in biology [38]. Also, there is an emphasis on the known 
pathways in pathway-based approaches [60], therefore the applicability of this approach may be 
limited by our current knowledge of biology. The mechanisms of many drugs are not entirely 
clear so their ‘pathways’ or gene-sets may be incompletely characterized. Finally, the 
directionality of effect may not be clear.  
Similarity-based drug repositioning 
Similarity between drug-drug and disease-disease pairs may be leveraged for drug repositioning. 
One of the characteristics of such similarity-based approaches is that they generally do not 
require detailed understanding of drug or disease mechanisms, and are able to consider high-
throughput omics data across many genes without restricting to the most significant ones. Note 
that similarity-based approaches is closely related to network-based approaches, however some 
algorithms have been specifically designed for the former and network-based methods usually 
involve modeling a larger variety of information (apart from similarity between drugs and 
diseases).  
Drug-drug similarity match 
Drug-drug similarity analysis begins with the comparison between the chemical and/or 
biological profiles of different drugs, after which drugs can be repositioned to the indications of 
another one if the two shared sufficient similarity. An example to illustrate this idea is the work 
by Napolitano et al.[66]. The authors first generated a drug similarity matrix by integrating 
multiple sources of information, such as similarity in transcriptomic changes after drug 
administration (from CMap), as well as similarity in drug target proteins and chemical structures. 
The authors integrated different sources of information via a machine learning (ML) framework 
and proposed candidates for repositioning based on similarity to the known drugs.   
Disease-disease similarity match 
It is reasonable to hypothesize that if two diseases are similar enough, then the drugs that are 
indicated for one disease may be repositioned to treat the other. This concept has been used in a 
number of studies in drug repositioning. For instance, Gottlieb et al. [67] proposed an algorithm 
(PREDICT) to combine multiple measures of drug-drug similarity and disease-disease similarity 
for repositioning. Later Wang et al. [68] combined the approach in PREDICT with drug and 
disease data from DrugBank, CMap, OFFSIDE (a side effect database from PharmGKB) and 
literature text mining to create a recommendation system for novel drug candidates. While the 
aforementioned studies did not directly utilize GWAS data, such data may be used to measure 
disease-disease similarity as well.  For example, as a proof of concept, Li et al. [47] examined 
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pairs of genetic variants shared between disease while considering eQTL information at the same 
time. They found that pairs of diseases that are genetically similar were also more likely to be 
comorbid in clinical samples. The study suggests genetic data from GWAS may also be used to 
assess ‘similarity’, which might have implications in drug repositioning.  
Limitations  
Similarity between drugs and diseases may not be easy to define. For example, some studies 
used CMap to ascertain drug-drug similarity, but there are limitations of the CMap database 
(please also refer to discussions in the next section), such as lack of appropriate tissue-specific 
cell lines in some occasions. How to integrate different sources of data to define similarity 
remains an open question. By its nature, this approach may tend to uncover candidates that are 
similar to the known drugs, and is less capable of revealing drugs with novel mechanisms of 
actions. It is possible that the drug candidates is already suggested by clinical experience due to 
their similarity with the known ones. Network-based approaches may also share similar 
shortcomings, due to similarity in their principles.  
Searching for reversed expression profiles between drugs and 
diseases  
A more distinct approach to repositioning is to compare the expression profiles of drugs against 
those of specific diseases. The core hypothesis is that if a drug produces an expression profile 
that is opposite to that of a disease, then the drug may be considered a repositioning candidate 
(due to its potential to ‘reverse’ disease-related expression profiles). This approach does not 
require knowledge of the drug mechanisms or even drug targets; it can be applied as long as 
drug-induced expression profiles are available. In addition, it utilizes GWAS data across multiple 
genes instead of focusing on only the top significant ones. As will be described later, the method 
is also readily available to any complex diseases/traits with GWAS summary statistics available. 
Compared to similarity or network-based methods, this approach may have a greater chance of 
uncovering drugs with new mechanisms of action.  
 
  To perform this kind of analysis, one would need the following components: (1) Drug-induced 
(differential) expression profile; (2) Disease-induced (differential) expression profile;  and (3) 
algorithms to determine the correlations between (1) and (2).  
 
  Publicly available data are available for drug-induced expression profiles. Popular choices 
include the Connectivity Map (CMap) [69] and its successor Library of Integrated Network-
based Cellular Signatures (LINCS) L1000 data [70]. CMap is a collection of expression profiles 
by applying ~1300 compounds on 5 human cancer cell lines, with expression profiles for ~7000 
genes as of Build 2. LINCS (L1000) is a database of much larger scale that contains about 
1328098 gene expression profiles as a result from the applications of ~42553 perturbagens. A set 
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of 1000 ‘landmark’ transcripts was directly measured while the expression levels of other genes 
were mainly computed by imputation. A comprehensive review about these resources is given by 
Musa et al. [71].  
   
  For the purpose of this review, we shall mainly discuss GWAS-derived data for component (2). 
While one may use RNA-seq or microarray data in patients to directly estimate component (2), 
as argued in [50], there are several advantages of using imputed expression profile from GWAS. 
For example, patients are often medicated before their samples are collected, which may affect 
their expression profiles. GWAS-imputed transcriptome is much less susceptible to confounding 
by medication or other environmental factors. In addition, expression can be imputed for a large 
variety of tissues, even for those (e.g. brain) which are difficult to access. The sample size of 
GWAS is also often much larger than standard RNA-seq or microarray studies on clinical 
samples. This approach of comparing GWAS-imputed expression against drug transcriptomes 
was proposed and adopted by So et al. [50] to prioritize repositioning candidates for psychiatric 
disorders. The method revealed numerous candidates supported by previous preclinical or 
clinical studies, and the approach was able to ‘re-discover’ known psychiatric medications for 
the respective disorders, despite having no prior knowledge of the drug indications.   
 
  Imputation of gene expression profiles could be performed by various tools, the most popular 
being PrediXcan [26] or its successor S-PrediXcan [72]. The latter is able to impute expression 
changes by GWAS summary statistics alone, which enhances the applicability of the above 
repositioning methodology as summary statistics are now widely available. Briefly, these tools 
first learn how SNPs may dictate gene expression levels from training data extracted from 
datasets such as GTEx, GEUVADIS and DGN. Based on the prediction model built, the tools 
can then predict or impute expression levels when presented with genotypes from new samples.  
Finally, for component (3) of the analysis, we need to assess the (anti-)correlation between the 
expression profiles from drugs and diseases. In particular, So et al. [50] adopted Spearman and 
Pearson correlation as well as Kolmogorov–Smirnov (KS) test to evaluate patterns of reversed 
expression.  
Limitations 
There are several limitations of this approach, many of which are also discussed in [50]. First, 
perturbation libraries such as CMap and L1000 are usually based on cell line data, meaning that 
all the limitations of cell line-based experiments may also apply. For instance, cell lines cannot 
model complex cell-cell or cell-ECM (extracellular matrix) interactions, and pharmacokinetic 
properties and dosage control are often experiment protocol-dependent [73]. Second, many of the 
cell lines are cancer cell lines; using them for expression profiling may not be optimal when the 
aim is to prioritize drugs for other diseases, such as psychiatric disorders or CVD. Third, not all 
therapeutically important drugs work by reversing gene expression profiles, although the 
approach appears to work reasonably well at least in psychiatric disorders. Finally, imputation of 
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expression profiles from GWAS data may not be as accurate as directly measuring the actual 
tissue-specific expression profiles from patient samples, although the latter is often difficult to 
collect. Some genes may be poorly imputed due to large environmental influence on gene 
expression [74], or that the original sample is not powerful enough to detect the eQTLs. 
Limitations of the GTEx sample discussed earlier also apply here.   
Network-based approaches 
Overview 
Network-based drug repositioning approaches aim to uncover novel drug-disease relationships 
by integrating a wide variety of biological information. A typical network consists of nodes 
(genes, protein, disease/trait, compounds) and edges (often weighted in biological settings) 
connecting the nodes. This approach is a popular and well-established drug repositioning 
technique which offers high flexibility, as it allows for consideration of multiple dimensions of 
data sources. The types of biological networks that are useful for drug repositioning include, for 
example, gene regulatory, gene-gene interaction, metabolic, drug-target interaction (DTI) and 
protein-protein interaction (PPI) [53] networks. It is preferable to integrate multiple biological 
networks in order to reduce noise and improve biological relevance [52,54]. After preparing a 
curated network of information, analyzing the graphs usually involves tools developed from 
graph theory. For drug repositioning, two types of network analysis approaches might be useful: 
clustering and propagation [75]. Briefly, clustering is a way of discovering subnetworks by the 
similarity of its elements, since biologically related entities should intuitively share a handful of 
underlying connections [76,77]. Clustering may reveal subnetworks and new relationships 
between drugs and diseases, fostering the discovery of drug candidates. Propagation approaches, 
as the name suggests, models the propagation of information from a source node to its 
surroundings [78]. Approaches such as random walk[79] may be used to assess the distance 
between a drug and a disease, thereby prioritizing drug candidates. For the purpose of this study, 
we shall not focus on discussing the general approaches of network-based drug repositioning 
which has already been extensively reviewed [51–55,80–83]. Instead, we shall focus on the role 
and contribution of GWAS data towards this type of drug repositioning. 
 
Using GWAS data in network-based drug repositioning 
GWAS data can provide richer information for disease-disease, disease-gene or drug-gene edges 
in biological networks, hence providing better repositioning candidates or new drug targets. In a 
recent work, Gaspar et al. built bipartite drug-target networks leveraging gene-based statistics 
from MAGMA and S-PrediXcan, accounting for both SNP-level associations and imputed 
transcriptomic changes. They also built an online tool Drug Targetor (drugtargetor.com) which 
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visualizes the resulting drug-target network. The authors built a network from GWAS of major 
depressive disorder, and suggested potential new drug candidates and their modes of actions [84]. 
   In another application, a network-based approach was used to analyze GWAS results of CVD 
[85]. The study began with pathway analysis of the significant SNPs from 16 GWAS datasets. 
The identified pathways were then mapped to the PPI network InWeb and analyzed using 
random walk. Next, the authors examined the topological properties of the identified clusters and 
prioritized CVD-associated genes that displayed high centrality and betweenness, which may be 
prioritized as potential drug targets. In another report, Shu et al. [86] studied shared genetic 
networks and key ‘driver genes’ for both CVD and T2D by a systems approach. They considered 
co-expression modules for CVD and type 2 diabetes (T2D), and incorporated gene regulatory 
networks from GIANT [87] and Bayesian networks constructed from CVD and T2D related 
tissues to prioritize key drivers. The potential driver genes or key regulators were further 
validated by cell culture and animal models. These genes served as useful targets for drug 
discovery or repositioning. While the above two examples were not solely aimed at drug 
repositioning, they showed how network-based methods may shed light on biological processes 
and help prioritize drug target genes.  
Limitations  
First, integrating different sources of networks can be tedious and challenging in terms of data 
cleaning, and this might require certain degree of understanding of the data and their biological 
meanings. Second, network analysis heavily rely on the similarity or closeness between different 
entities [55], therefore the repositioning results may be concentrated around the ‘nearby 
pharmacological space’; it may be relatively difficult to uncover drugs with novel mechanisms. 
Also, the strengths of similarity between nodes (i.e. edge strengths) are often hard to define. In 
addition, limitations in data sources could affect the performance of network-based analysis 
methods, for example the reliability and completeness of interactome data [88] and the difficulty 
in constructing accurate PPI networks [89]. Finally, the complicated nature of network structures 
makes parameter optimization a key issue when analyzing the data with network-based 
algorithms [90]. 
Conclusion and Future Directions 
Despite more than 7000 GWAS has been conducted to date, comparatively few studies have 
systematically analyzed the potential of GWAS in drug discovery or repositioning. With growing 
resources from biobanks (e.g. the UK Biobank) and increasing availability of GWAS data, such 
kind of data should provide a very rich resource for guiding drug discovery/repositioning. Indeed, 
as discussed above, a number of studies have provided early evidence that human genomics data 
from GWAS might improve the success of drug development, or that repositioning strategies 
based on GWAS are able to ‘re-discover’ known drugs for diseases and/or suggest reasonable 
new candidates.  
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  We focus on computational approaches to prioritize drug candidates in this review, but we 
should emphasize that further experimental and clinical studies are necessary to confirm the 
findings. Computational or bioinformatics approaches helps to narrow down the search space 
and improve the success rate of development by prioritizing the best candidates, but they are not 
designed to provide confirmatory evidence. Nevertheless, given the huge cost and long time 
involved in developing a new drug, even a tiny improvement in success rate would translate to 
very substantial savings in absolute terms.  
 
  We hereby make a few comments to highlight several general limitations and directions for 
further research. First, to improve the accuracy of GWAS-based drug-repositioning studies, there 
is a need for more high-quality data, including but not limited to GWAS with large cohort sizes 
and richer phenotypes, GTEx (or similar projects) on more tissues and larger sample sizes, 
perturbation libraries that involve more complex drug testing models etc. Second, new statistical 
methods have emerged to ascertain not only associations but also causal relationships between 
exposure (or risk factors) and outcomes; one of the most prominent methods is Mendelian 
Randomization (MR) [91]. A few studies have suggested that MR may be used to model the 
effects or side-effects of drugs (with known targets). This may have implications for drug 
discovery or repositioning although further development in methodology may be required[92–
94]. Third, machine learning (ML) and artificial intelligence are among the fastest growing areas 
in recent years. ML approaches such as deep learning and other methods hold great promise for 
accelerating drug discovery/repositioning, as they may be able to discover and predict with 
higher accuracy the complex patterns and relationships between genes, drugs and diseases [95–
98]. For example, ML methods may be used to capture complex relationships between drug 
transcriptome and the drug’s treatment potential for specific diseases [99]. For diseases with high 
heterogeneity, one type of drug may only be useful for a subgroup of patients[100]. 
Unsupervised learning methods may help to subtype diseases more accurately, enhancing the 
success rate of drug development [101]. Finally, GWAS is a very rich source of omics data, but 
integration with other forms of human genomic data, such as those from exome sequencing, 
transcriptomics and epigenomics studies will further improve the reliability of repositioning. In 
the same vein, another important direction is the integration of large-scale electronic health 
records (EHR) with multi-omics data in drug development. As emphasized in this review, each 
repositioning method has its own strengths and limitations. An important future direction is to 
integrate different methodologies for optimal prediction of drug candidates.  
 
 
Acknowledgements 
H.C.S. was supported partially by the Lo Kwee Seong Biomedical Research Fund, a Direct Grant 
from The Chinese University of Hong Kong, RGC Collaborative Research Fund C4054-17WF, 
and HMRF grant (06170506).  
15 
 
Conflicts of interest 
The authors declare no competing interests.  
 
 
Legends (Figure 1) 
1. Risk loci for a particular disease can be identified from GWAS.  
2. Several approaches to drug repositioning using GWAS data are highlighted:  
(a) Selection of top candidate genes: the risk loci from GWAS data can be mapped to the most 
likely relevant genes with functional annotation and eQTL data. If the identified candidate gene 
is druggable and the drug is not already indicated for the disease, the drug may serve as a 
repositioning candidate.  
(b) Pathway or gene-set analysis approach: the identified candidate gene(s) are placed in the 
context of its pathways; drugs that target members of the same pathway are potential drug 
candidates. Alternatively, the entire set of GWAS data may be used to derive gene-based 
statistics, and enrichment test performed to look for drugs whose targets/effector genes achieve 
higher significance (lower p-values) than expected as a whole.  
(c) Looking for reversed expression patterns between drugs and diseases: The core hypothesis is 
that if a drug produces an expression profile that is opposite to that of a disease, then the drug 
may be considered a repositioning candidate (due to its potential to ‘reverse’ disease-related 
expression profiles).  
(d) Network-based analysis: Integration of multiple sources of data such as drugs, proteins, genes 
and diseases relationships to construct biological networks. Further analysis with computational 
methods such as random walk may reveal novel drug-disease connections. The principle of this 
method is close to 'similarity-based' methods (see main text) for drug repositioning, but network-
based method usually integrates a greater variety of information.  
3. Finally, drugs can be prioritized as repositioning candidates and verified in further 
experimental and clinical studies.  
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